# Nuclide record neuroendocrine (indication). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/indications/neuroendocrine/>
  a schema:MedicalCondition ;
  nuclide:kind "indication" ;
  schema:identifier "neuroendocrine" ;
  schema:name "Neuroendocrine tumours"@en ;
  schema:alternateName "Gastrointestinal Neuroendocrine Tumors"@en, "Pancreatic Neuroendocrine Tumors (Islet Cell Tumors)"@en ;
  schema:description "A family of usually slow-growing tumours that start in hormone-producing cells of the gut, pancreas and lungs. They pioneered the idea of using the same molecule to see a tumour on a scan and then to treat it with radiation."@en ;
  schema:url <https://nuclide.cc/indications/neuroendocrine/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Neuroendocrine_tumor> ;
  owl:sameAs <http://www.wikidata.org/entity/Q1981276> ;
  schema:citation <https://en.wikipedia.org/wiki/Neuroendocrine_tumor> ;
  nuclide:tag "endocrine", "spike" ;
  nuclide:related <https://nuclide.cc/pairings/sstr-pet-to-prrt/>, <https://nuclide.cc/pairings/prrt-then-alpha-net/>, <https://nuclide.cc/roadmaps/radiopharma-roadmap/>, <https://nuclide.cc/pairings/beta-then-alpha/>, <https://nuclide.cc/isotopes/lu-177/>, <https://nuclide.cc/isotopes/ac-225/>, <https://nuclide.cc/isotopes/pb-212/> ;
  nuclide:technologies <https://nuclide.cc/technologies/radioligand-therapy/>, <https://nuclide.cc/technologies/targeted-alpha-therapy/>, <https://nuclide.cc/technologies/pet/>, <https://nuclide.cc/technologies/sstr-pet/>, <https://nuclide.cc/technologies/prrt/>, <https://nuclide.cc/technologies/pet-ct/>, <https://nuclide.cc/technologies/radioembolisation-tare/> ;
  nuclide:targets <https://nuclide.cc/targets/sstr2/>, <https://nuclide.cc/targets/dll3/> ;
  nuclide:drugs <https://nuclide.cc/drugs/iobenguane-i-131/> ;
  nuclide:companies <https://nuclide.cc/companies/sinotau-pharmaceutical/>, <https://nuclide.cc/companies/novartis/>, <https://nuclide.cc/companies/itm/>, <https://nuclide.cc/companies/orano-med/>, <https://nuclide.cc/companies/radiomedix/>, <https://nuclide.cc/companies/rayzebio/>, <https://nuclide.cc/companies/bms/>, <https://nuclide.cc/companies/pfizer/> ;
  nuclide:institutions <https://nuclide.cc/institutions/mskcc/>, <https://nuclide.cc/institutions/heidelberg-nct/>, <https://nuclide.cc/institutions/royal-marsden/> ;
  nuclide:terms <https://nuclide.cc/terms/net-grade-ki67/>, <https://nuclide.cc/terms/theranostics/>, <https://nuclide.cc/terms/alpha-vs-beta/>, <https://nuclide.cc/terms/dosimetry/> ;
  nuclide:trials <https://nuclide.cc/trials/netter-1/>, <https://nuclide.cc/trials/nct05459844/>, <https://nuclide.cc/trials/nct06398444/>, <https://nuclide.cc/trials/nct04919226/> ;
  nuclide:pipeline <https://nuclide.cc/drugs/ryz101/>, <https://nuclide.cc/drugs/itm-11/>, <https://nuclide.cc/trials/compete/>, <https://nuclide.cc/drugs/alphamedix/>, <https://nuclide.cc/trials/alphamedix-02/>, <https://nuclide.cc/trials/action-1/>, <https://nuclide.cc/technologies/prrt/>, <https://nuclide.cc/technologies/sstr-pet/>, <https://nuclide.cc/drugs/cabozantinib/>, <https://nuclide.cc/ideas/idea-net-dosimetry-prrt/>, <https://nuclide.cc/ideas/idea-net-antagonist-ligands/>, <https://nuclide.cc/pairings/prrt-then-alpha-net/>, <https://nuclide.cc/targets/dll3/> ;
  nuclide:standardOfCare <https://nuclide.cc/drugs/lutathera/>, <https://nuclide.cc/drugs/ryz101/>, <https://nuclide.cc/technologies/sstr-pet/>, <https://nuclide.cc/terms/net-grade-ki67/>, <https://nuclide.cc/drugs/lutathera/>, <https://nuclide.cc/technologies/prrt/>, <https://nuclide.cc/drugs/lutathera/>, <https://nuclide.cc/drugs/itm-11/>, <https://nuclide.cc/trials/compete/>, <https://nuclide.cc/drugs/everolimus/>, <https://nuclide.cc/trials/radiant-3-4/>, <https://nuclide.cc/drugs/sunitinib/>, <https://nuclide.cc/drugs/cabozantinib/>, <https://nuclide.cc/trials/cabinet/>, <https://nuclide.cc/technologies/radioembolisation-tare/>, <https://nuclide.cc/drugs/ryz101/>, <https://nuclide.cc/trials/action-1/>, <https://nuclide.cc/drugs/alphamedix/>, <https://nuclide.cc/pairings/prrt-then-alpha-net/> .